Original language | English (US) |
---|---|
Pages (from-to) | 294-296 |
Number of pages | 3 |
Journal | JAMA Oncology |
Volume | 6 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2020 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA Oncology, Vol. 6, No. 2, 02.2020, p. 294-296.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Association of Sex with Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer
AU - Diefenhardt, Markus
AU - Ludmir, Ethan B.
AU - Hofheinz, Ralf Dieter
AU - Ghadimi, Michael
AU - Minsky, Bruce D.
AU - Rödel, Claus
AU - Fokas, Emmanouil
N1 - Funding Information: Conflict of Interest Disclosures: Dr Reece reported grants and personal fees from Janssen, Celgene, Amgen, and Takeda; personal fees from Karyopharm; and grants from Otsuka, Merck, and Bristol-Myers Squibb. Dr Trudel reported grants and personal fees from Janssen, Celgene, Amgen, and GlaxoSmithKline; personal fees from Sanofi and Karyopharm; and grants from Genentech. Dr Tiedemann reported grants from Terry Fox Research Institute and personal fees from Janssen, Amgen, Roche, Celgene, and Takeda. No other disclosures were reported. Funding Information: Funding/Support: Funding for this study was provided in part by the Terry Fox Research Institute. Funding Information: Additional Contributions: We thank the National Microbiology Lab and the Public Health Ontario Laboratory for contributing public health–level information and the myeloma clinical trials team at Princess Margaret Cancer Centre for providing visit data. We thank the Terry Fox Research Institute for support (Pan-Canadian Myeloma Program Project grant to Drs Tiedemann and Trudel). Funding Information: Bristol-Myers Squibb, Eli Lilly and Company, and Medac; personal fees from Roche, Sanofi, Eli Lilly and Company, Merck Serono, Amgen, Servier Laboratories, Merck Sharp & Dohme, and Bristol-Myers Squibb; and his institution received research funding from Sanofi, Medac, and German Cancer Aid. Dr Rödel reported receiving research funding from German Cancer Aid. No other disclosures were reported. Funding/Support: The CAO/ARO/AIO-94 and CAO/ARO/AIO-04 trials were funded by grants (70-578, 106-757) of the German Cancer Aid.
PY - 2020/2
Y1 - 2020/2
UR - http://www.scopus.com/inward/record.url?scp=85076152415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076152415&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2019.5102
DO - 10.1001/jamaoncol.2019.5102
M3 - Letter
C2 - 31804659
AN - SCOPUS:85076152415
SN - 2374-2437
VL - 6
SP - 294
EP - 296
JO - JAMA Oncology
JF - JAMA Oncology
IS - 2
ER -